Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 448.44% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 448.44% | -- | -- |
| Cost of Revenue | -16.47% | -18.39% | -20.19% | -24.78% | -44.11% |
| Gross Profit | 18.26% | 19.55% | 20.66% | 24.78% | -633.67% |
| SG&A Expenses | -29.50% | -26.37% | -19.42% | -22.97% | -34.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.19% | -21.89% | -19.86% | -24.01% | -40.87% |
| Operating Income | 23.20% | 22.54% | 20.13% | 24.01% | -71.54% |
| Income Before Tax | 22.08% | 104.53% | 103.72% | 60.06% | 3.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.08% | 104.53% | 103.72% | 60.06% | 3.06% |
| Earnings from Discontinued Operations | -- | -- | -100.00% | 612.62% | 746.30% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.29% | 4,088.24% | 121.17% | 153.03% | 188.23% |
| EBIT | 23.20% | 22.54% | 20.13% | 24.01% | -71.54% |
| EBITDA | 23.21% | 22.45% | 19.70% | 23.90% | -81.51% |
| EPS Basic | -155.01% | 2,944.94% | 113.11% | 147.77% | 176.83% |
| Normalized Basic EPS | 31.31% | 40.98% | 67.67% | 44.26% | -35.76% |
| EPS Diluted | -155.14% | 2,000.25% | 112.77% | 147.66% | 175.96% |
| Normalized Diluted EPS | 31.32% | 41.02% | 67.70% | 44.28% | -33.93% |
| Average Basic Shares Outstanding | 11.82% | 14.02% | 19.82% | 21.02% | 22.04% |
| Average Diluted Shares Outstanding | 11.82% | 14.10% | 19.91% | 21.06% | 21.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |